ACTU (Actuate Therapeutics) Common Stock: $0.00 Mil (As of Mar. 2026)


ACTU Actuate Therapeutics Inc ACTU
14 GF Score
Price $1.82
View Full Analysis

What is Actuate Therapeutics Common Stock?

Actuate Therapeutics ACTU -14.29% 14 Common Stock is $0.00 Mil as of Mar. 2026. GuruFocus rates ACTU with a GF Score™ of 14/100.

Actuate Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Actuate Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actuate Therapeutics Common Stock Chart

Actuate Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Common Stock
0.00 0.00 0.00 0.00

Actuate Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ACTU
14GF Score
Actuate Therapeutics Inc ACTU
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actuate Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.00 Mil mean?
Actuate Therapeutics (ACTU) has a Common Stock of $0.00 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Actuate Therapeutics and its competitors.
Is Actuate Therapeutics' Common Stock too high?
Actuate Therapeutics' current Common Stock is $0.00 Mil. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' Common Stock compare to AURX and ESLA?
Actuate Therapeutics' Common Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Actuate Therapeutics and its competitors. Actuate Therapeutics's current Common Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current Common Stock of $0.00 Mil. The current Common Stock is $0.00 Mil. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current Common Stock is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actuate Therapeutics Business Description

Address 1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score

Get the complete analysis for ACTU

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.82
Price